Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

106
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

128
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

Dihydropyrimidine Dehydrogenase Levels in Colorectal Cancer Cells Treated with a Combination of Heat Shock Protein 90 Inhibitor and Oxaliplatin or Capecitabine

Pages

  439-444

Abstract

 Purpose: Dihydropyrimidine dehydrogenase (DPD) is the principal enzyme in the catabolism of fluoropyrimidine drugs including Capecitabine. A recent report has suggested that Oxaliplatin chemotherapy is associated with elevated DPD levels and chemoresistance pattern. As a newly developed chemotherapeutic agent, 17-allyloamino-17-demethoxy-geldanamycin (17-AAG) can be effective in combination therapy with Oxaliplatin and Capecitabine in Colorectal cancer (CRC). DPD expression level can be a predictive factor in Oxaliplatin and Capecitabine-based chemotherapy. We evaluated DPD in mRNA and protein levels with new treatments: 17-AAG in combination with Oxaliplatin and Capecitabine in HT-29 and HCT-116 cell lines. Methods: Drug sensitivity was determined by the water-soluble tetrazolium-1 assay in a previous survey. Then, we evaluated the expression levels of DPD and its relationship with the chemotherapy response in Capecitabine, Oxaliplatin, and 17-AAG treated cases in single and combination cases in two panels of CRC cell lines. DPD gene and protein expression levels were determined by real-time polymerase chain reaction and western blotting assay, respectively. Results: DPD gene expression levels insignificantly increased in single-treated cases versus untreated controls in both cell lines versus controls. Then, the Capecitabine and Oxaliplatin were added in double combinations, where DPD gene and protein expression increased in combination cases compared to pre-chemotherapy and single drug treatments. Conclusion: The elevated levels of cytotoxicity in more effective combinations could be related to a different mechanism apart from DPD mediating effects or high DPD level in the remaining resistance cells (drug-insensitive cells), which should be investigated in subsequent studies.

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    Mohammadian, Mahshid, Zeynali Moghaddam, Shima, KHADEM ANSARI, MOHAMMAD HASSAN, RASMI, YOUSEF, Fathi Azarbayjani, Anahita, & KHERADMAND, FATEMEH. (2019). Dihydropyrimidine Dehydrogenase Levels in Colorectal Cancer Cells Treated with a Combination of Heat Shock Protein 90 Inhibitor and Oxaliplatin or Capecitabine. ADVANCED PHARMACEUTICAL BULLETIN, 9(3), 439-444. SID. https://sid.ir/paper/755844/en

    Vancouver: Copy

    Mohammadian Mahshid, Zeynali Moghaddam Shima, KHADEM ANSARI MOHAMMAD HASSAN, RASMI YOUSEF, Fathi Azarbayjani Anahita, KHERADMAND FATEMEH. Dihydropyrimidine Dehydrogenase Levels in Colorectal Cancer Cells Treated with a Combination of Heat Shock Protein 90 Inhibitor and Oxaliplatin or Capecitabine. ADVANCED PHARMACEUTICAL BULLETIN[Internet]. 2019;9(3):439-444. Available from: https://sid.ir/paper/755844/en

    IEEE: Copy

    Mahshid Mohammadian, Shima Zeynali Moghaddam, MOHAMMAD HASSAN KHADEM ANSARI, YOUSEF RASMI, Anahita Fathi Azarbayjani, and FATEMEH KHERADMAND, “Dihydropyrimidine Dehydrogenase Levels in Colorectal Cancer Cells Treated with a Combination of Heat Shock Protein 90 Inhibitor and Oxaliplatin or Capecitabine,” ADVANCED PHARMACEUTICAL BULLETIN, vol. 9, no. 3, pp. 439–444, 2019, [Online]. Available: https://sid.ir/paper/755844/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top